Amino Acid Stress Response Genes Contribute to a 25-Fold Increased Risk of L-Asparaginase-Induced Hypersensitivity.
Saved in:
| Title: | Amino Acid Stress Response Genes Contribute to a 25-Fold Increased Risk of L-Asparaginase-Induced Hypersensitivity. |
|---|---|
| Authors: | Anderson SJ; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Scott EN; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Raack EJ; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Chang WC; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, Canada., Córdova-Delgado M; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, Canada., Trueman JN; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, Canada., Loucks CM; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Rassekh SR; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Ross CJD; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada., Carleton BC; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, Canada. |
| Corporate Authors: | Canadian Pharmacogenomics Network for Drug Safety (CPNDS) consortium |
| Source: | Pediatric blood & cancer [Pediatr Blood Cancer] 2025 Jun; Vol. 72 (6), pp. e31668. Date of Electronic Publication: 2025 Mar 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
